{
    "Trade/Device Name(s)": [
        "Lumipulse G whole PTH",
        "Lumipulse G whole PTH Immunoreaction Cartridges"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K190702",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150879"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEW"
    ],
    "Summary Letter Date": "July 29, 2019",
    "Summary Letter Received Date": "July 30, 2019",
    "Submission Date": "August 20, 2019",
    "Regulation Number(s)": [
        "21CFR862.1545"
    ],
    "Regulation Name(s)": [
        "Parathyroid hormone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Parathyroid hormone (PTH, 1-84)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Sample Cups",
        "Sample Tubes",
        "Serum Separator Tube (SST)",
        "K2EDTA tube",
        "Lithium Heparin tube",
        "Sodium Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LUMIPULSE G System",
        "LUMIPULSE G1200 System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent Enzyme Immunoassay (CLEIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Sandwich assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Immunoreaction Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Lumipulse G whole PTH CLEIA assay for quantitative measurement of parathyroid hormone (1-84) in human serum and plasma on the LUMIPULSE G System",
    "Indications for Use Summary": "For in vitro diagnostic use; quantitative measurement of PTH (1-84) in human serum and plasma for differential diagnosis of hypercalcemia and hypocalcemia due to disorders of calcium metabolism",
    "fda_folder": "Clinical Chemistry"
}